

Dear Lori

Further to the e mail below inviting comments on the assessment report, Boehringer-Ingelheim has the following comments:

- In relation to tables 6.38 - 6.41 (pages 131-134) it would be useful to clarify in the accompanying text the definitions for the different incremental analyses carried out (referred to as column headings in the tables as "incremental analysis 1", "incremental analysis 2" and "incremental analysis vs. 3")
- Using the assessment group health economics model, cost effectiveness analyses have been reported which estimate ICERs with and without the application of TA90 guidance as it relates to limiting the use with IS / TIA patients of modified release dipyridamole plus aspirin to 2 years or allowing life time use (eg. in tables 6.38 - 6.41 (pages 131-134)); the relevance of this information is useful for decision making to determine whether limiting use to 2 years or not is the more cost effective option and its consideration would be valuably included in the relevant section of the discussion of the results (ie. pages 160 and 163) and in the executive summary (pages 17 and 21)

Regards

[Redacted]

[Redacted]

[Redacted]

Boehringer Ingelheim Ltd

Tel: [Redacted]

Fax: [Redacted]

Mobile: [Redacted]

[Redacted]